ALSO NOTED: Osiris files IPO; Amgen initiates kidney disease study; and much more...

> Baltimore-based stem cell therapeutic company Osiris Therapeutics announced an IPO at 3.5 million shares for about $11 to $13 each. Report

> Chutes & Ladders: Ann, Arbor, MI-based Aastrom Biosciences has named George W. Dunbar CEO and president. Release

> Melbourne-based CSL Limited will acquire biotech Zenyth Therapeutics for about $108 million. Release

> Amgen is initiating a 3,800-person study of Sensipar/Mimpara for kidney disease. Report

And Finally... The Senate will continue to debate three stem cell bills which President Bush has pledged to veto if passed. Article (WSJ sub. req.)